建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
The Phase 3 international MRCT study results of the diabetic foot ulcer new drug, Fespixon have been accepted for oral presentation at the 57th EASD Annual Meeting
A Chinese patent titled "USE OF FLAVOIDS IN MANUFACTURING COMPOSITIONS FOR WOUND HEALING." has been granted.
The annual shareholders' meeting will be postponed in accordance with the instructions of FSC.
A Chinese patent titled ”Use of Plectranthus amboinicus extract in manufacturing compositions for anA Taiwan patent titled "Biomarkers for lung cancer stem cells" has been granted
A Chinese patent titled ”Use of Plectranthus amboinicus extract in manufacturing compositions for anti-microbial effect”has been granted.
A Taiwan patent titled "Method for treating cancer using cd14 antagonists" has been granted.
Oneness received approval by TFDA on the phase 2 clinical trial application for FB704A, a fully-human anti-IL6 antibody new drug, in severe asthma.
Oneness announces that Nanchou manufacturing site has been GMP and GDP certified by MOHW
Oneness has submitted the phase 2 clinical trial application for FB704A, a fully-human anti-IL6 antibody new drug, in severe asthma to TFDA via fast track.
An Indian patent on the Anti-CεmX (FB825) antibody was granted.
Oneness was notified by US FDA today that the DFU new drug (ON101), has been granted the Fast Track Designation, which will facilitate NDA process of ON101 in US.
Oneness has received the letter from MOHW with regards to collection the drug license of DFU new drug: Fespixon cream.
Oneness Biotech Co., LTD receives a European patent on OB318, a new drug in development for liver cancer.
Oneness Biotech Co.,LTD receives a Taiwan patent on antagonistic PDL1 aptamers.
Oneness has been notified by Microbio Shanghai Co., Ltd. that CDE under NMPA accepted NDA application by writing for, the DFU new drug: ON101
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?